8 December 2017

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Accrol Group Holdings plc

(AIM: ACRL)

Result of General Meeting

Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, announces that at its general meeting held earlier today, all resolutions were approved. Following the approval of these resolutions, the Placing, the Revised Banking Facilities (as described in the Company's announcement of 20 November 2017 titled "Proposed Placing of £18m and Lifting of Suspension") and the appointment of the proposed Director, Dan Wright, remain subject only to admission of the new ordinary shares being issued pursuant to the Placing, which is expected to occur at 8am on Monday 11 December 2017.  

Enquiries:

Accrol Group Holdings plc                                                                                                    Tel: +44 (0) 1254 278 844

Gareth Jenkins, CEO

James Flude, Finance Director

Zeus Capital Limited (Nominated Adviser & Broker)

Dan Bate / Andrew Jones                                                                                                      Tel: +44 (0) 161 831 1512

Dominic King / John Goold                                                                                                   Tel: +44 (0) 203 829 5000

Belvedere Communications Limited                                                                                 Tel: +44 (0) 203 567 0510

Cat Valentine (cvalentine@belvederepr.com)                                                             Mob: +44 (0) 7715 769 078

Kim van Beeck (kvbeeck@belvederepr.com)                                                                Mob: +44 (0) 7477 967 446